Agios Pharmaceuticals (AGIO) Competitors $32.42 +0.60 (+1.89%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AGIO vs. ROIV, RVMD, LNTH, BPMC, BBIO, LEGN, ELAN, CYTK, NUVL, and GRFSShould you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Nuvalent (NUVL), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Agios Pharmaceuticals vs. Roivant Sciences Revolution Medicines Lantheus Blueprint Medicines BridgeBio Pharma Legend Biotech Elanco Animal Health Cytokinetics Nuvalent Grifols Roivant Sciences (NASDAQ:ROIV) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, community ranking, earnings, profitability, dividends, media sentiment and analyst recommendations. Which has better valuation & earnings, ROIV or AGIO? Roivant Sciences has higher revenue and earnings than Agios Pharmaceuticals. Roivant Sciences is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$124.79M65.04$4.35B$5.651.97Agios Pharmaceuticals$26.82M68.94-$352.09M$11.362.85 Does the media favor ROIV or AGIO? In the previous week, Roivant Sciences and Roivant Sciences both had 7 articles in the media. Roivant Sciences' average media sentiment score of 1.33 beat Agios Pharmaceuticals' score of 0.29 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ROIV or AGIO more profitable? Roivant Sciences has a net margin of 3,827.42% compared to Agios Pharmaceuticals' net margin of 2,051.38%. Agios Pharmaceuticals' return on equity of -2.93% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences3,827.42% -14.65% -13.19% Agios Pharmaceuticals 2,051.38%-2.93%-2.58% Does the MarketBeat Community favor ROIV or AGIO? Agios Pharmaceuticals received 439 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 77.27% of users gave Roivant Sciences an outperform vote while only 67.03% of users gave Agios Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRoivant SciencesOutperform Votes5177.27% Underperform Votes1522.73% Agios PharmaceuticalsOutperform Votes49067.03% Underperform Votes24132.97% Do analysts prefer ROIV or AGIO? Roivant Sciences currently has a consensus target price of $17.93, indicating a potential upside of 60.79%. Agios Pharmaceuticals has a consensus target price of $56.33, indicating a potential upside of 73.76%. Given Agios Pharmaceuticals' higher possible upside, analysts plainly believe Agios Pharmaceuticals is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Agios Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders and institutionals hold more shares of ROIV or AGIO? 64.8% of Roivant Sciences shares are owned by institutional investors. 7.9% of Roivant Sciences shares are owned by insiders. Comparatively, 4.9% of Agios Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, ROIV or AGIO? Roivant Sciences has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. SummaryRoivant Sciences beats Agios Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGIO vs. The Competition Export to ExcelMetricAgios PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.85B$6.22B$5.20B$9.02BDividend YieldN/A2.94%5.13%4.03%P/E Ratio2.856.5073.9915.38Price / Sales68.94330.311,269.0383.23Price / CashN/A61.4443.7535.97Price / Book2.236.055.324.80Net Income-$352.09M$154.62M$122.60M$224.91M7 Day Performance-5.81%-1.70%-0.21%1.47%1 Month Performance-16.91%2.75%3.74%4.66%1 Year Performance52.06%2.60%27.15%20.83% Agios Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGIOAgios Pharmaceuticals3.81 of 5 stars$32.42+1.9%$56.33+73.8%+49.3%$1.85B$26.82M2.85390Short Interest ↑ROIVRoivant Sciences3.689 of 5 stars$10.74+1.0%$17.93+66.9%+3.6%$7.82B$129.13M1.90860Insider TradeOptions VolumePositive NewsRVMDRevolution Medicines4.4701 of 5 stars$42.57+1.9%$66.25+55.6%+50.2%$7.16B$742,000.00-11.86250News CoveragePositive NewsLNTHLantheus4.5448 of 5 stars$94.65-1.3%$131.86+39.3%+65.5%$6.58B$1.50B15.75700Analyst ForecastShort Interest ↑BPMCBlueprint Medicines1.6713 of 5 stars$103.36+18.2%$122.72+18.7%+38.6%$6.57B$434.42M-48.99640Analyst ForecastInsider TradeShort Interest ↑Analyst RevisionGap UpHigh Trading VolumeBBIOBridgeBio Pharma4.0937 of 5 stars$33.73+16.0%$48.08+42.5%-8.5%$6.37B$217.77M-14.00400Short Interest ↑High Trading VolumeLEGNLegend Biotech2.5097 of 5 stars$32.50-3.3%$80.62+148.0%-45.5%$5.94B$520.18M-34.211,800Short Interest ↓News CoverageELANElanco Animal Health4.4179 of 5 stars$11.72+2.5%$16.43+40.2%-18.8%$5.79B$4.45B29.309,800CYTKCytokinetics4.3227 of 5 stars$46.71+0.2%$83.64+79.1%-46.6%$5.51B$7.53M-8.68250Analyst ForecastNUVLNuvalent1.797 of 5 stars$72.09-5.9%$112.36+55.9%+2.7%$5.12BN/A-20.7840Analyst ForecastInsider TradeNews CoverageGRFSGrifols2.0517 of 5 stars$7.23-0.8%N/A+7.2%$4.97B$7.01B5.9326,300Positive NewsGap Down Related Companies and Tools Related Companies Roivant Sciences Alternatives Revolution Medicines Alternatives Lantheus Alternatives Blueprint Medicines Alternatives BridgeBio Pharma Alternatives Legend Biotech Alternatives Elanco Animal Health Alternatives Cytokinetics Alternatives Nuvalent Alternatives Grifols Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AGIO) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
